Neogenomics (NEO) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Neogenomics (NEO) do?
Neogenomics Inc (NEO) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Runs specialized clinical laboratories providing molecular, cytogenetic, and pathology testing to oncologists. It is worth $1.95B on the market and sold $787.29M over the last year.
- Market cap
- $1.95B
- P/E ratio
- None (reported a loss)
- Annual sales
- $787.29M
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Brief updated
- Nov 16, 2026
Brands and businesses behind NEO
- RaDaR: Tracks minimal residual disease using personalized liquid biopsy panels, charging fees to clinical trial sponsors and healthcare providers.
- Inivata: Develops circulating tumor DNA liquid biopsy technology, generating revenue from oncology research collaborations and clinical test processing.
- NeoTYPE: Offers targeted multi-gene tumor sequencing profiles, billing insurers and hospitals for analyzing specific solid tumors and blood cancers.
NEO’s flags, in plain English
Each flag is a number from Neogenomics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.
Stupid Cash
Can pay this year's bills 3.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 56% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 42.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Burning Cash
Losing money, profit margin of -4.1%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about NEO
How big is Neogenomics?
Neogenomics’ market cap is $1.95B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $787.29M: what customers paid the company over the last year, before any costs.
What is NEO’s P/E ratio?
NEO has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with NEO?
Shifts in Medicare and private insurance reimbursement rates reduce the revenue earned per completed test. That is one risk on Neogenomics’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Neogenomics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. NEO’s filings on SEC.gov. The Margin Monkey is research, not advice.
